Wellbutrin for Depression

Bupropion is the antidepressant you get pointed toward when serotonin looks like the problem rather than the solution. Wellbutrin XL is labeled for major depressive disorder and for preventing seasonal major depressive episodes, and the same molecule appears as Wellbutrin SR under a separate label covering major depressive disorder only. Neither label mentions panic disorder, generalized anxiety or obsessive compulsive disorder, which is where a large share of SSRI prescribing also sits.

That narrower indication is your first clue that this drug behaves differently.

The tablets are not interchangeable milligram for milligram. Wellbutrin XL opens at 150 mg once daily and may move to 300 mg once daily after four days for depression, or after a week for the seasonal indication. Wellbutrin SR runs 150 mg twice daily at least eight hours apart instead. Both labels tell you to swallow the tablet whole rather than crush, divide or chew it, since dumping an extended-release dose all at once is precisely what the coating exists to prevent.

The cleanest comparison pooled the raw trial data from seven randomized trials: 732 assigned to bupropion, 731 to an SSRI and 512 to placebo. Carrying the last observation forward, response was 62 percent on bupropion and 63 percent on an SSRI, with remission at 47 percent in both arms. Placebo delivered 51 percent response and 36 percent remission, and both drugs beat it convincingly. The honest reading is parity on symptom relief.

One caveat deserves more attention than it usually gets. In two identical eight-week trials designed around sexual functioning, bupropion XL failed to separate from placebo on the primary depression scale at the conventional threshold while escitalopram did. Bupropion also did not differ statistically from escitalopram on that scale, on response or on remission. Trials can fail to detect a real effect, and these were powered for a different question, but a page that quotes their sexual-function numbers owes you their efficacy result too.

On the common belief that bupropion is a poor choice when depression comes with anxiety, the pooled evidence pushes back. Ten double-blind studies covering 943 men and 1,179 women produced 64 pairwise comparisons of which exactly one reached significance, and that one did not hold up on the continuous measure. Separately, an eight-week trial found bupropion SR statistically superior to placebo on every depression scale used while sertraline was not.

This is the reason bupropion gets prescribed. The seven-trial pooled analysis concluded that bupropion caused no more sexual dysfunction than placebo, while the SSRI arms produced more somnolence and diarrhea. A review of the wider literature put treatment-induced sexual dysfunction on SSRIs somewhere between 30 and 60 percent, against 10 percent or less for bupropion. Those are not small differences, and they are the single most common reason an antidepressant quietly stops being taken. The head-to-head numbers hold up. In the pooled escitalopram trials, orgasm dysfunction at week eight ran 15 percent on bupropion XL, 30 percent on escitalopram and 9 percent on placebo, with worsened sexual functioning at 20, 36 and 15 percent. An earlier trial recruiting only adults with normal baseline sexual functioning found significantly more orgasm dysfunction on sertraline than on bupropion SR.

Two independent designs, same direction, and the effect size is large enough to matter clinically.

Weight moves the other way from most antidepressants. In the sustained-release depression trials, 3 percent gained more than five pounds at 300 mg against 4 percent on placebo, while 14 percent lost more than five pounds against 6 percent. Over up to six months in the seasonal trials, weight loss of five pounds or more reached 23 percent on the extended-release tablet versus 11 percent on placebo. The bill arrives as stimulation: in those same trials insomnia ran 20 percent against 13 percent, dry mouth 26 against 15, and 9 percent stopped for adverse reactions against 5 percent.

The contraindication list is unusually specific for an antidepressant, and every item on it traces back to seizure threshold. The label bars use in seizure disorder, current or prior bulimia or anorexia nervosa, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs. Monoamine oxidase inhibitors need a two-week separation in either direction. Hypersensitivity is also listed, with anaphylactoid reactions and Stevens-Johnson syndrome reported after marketing.

The eating-disorder contraindication is not defensive boilerplate. It traces to a 1988 placebo-controlled trial in bulimia where four of the fifty-five assigned to bupropion had grand mal seizures, and the investigators concluded that bupropion should not be given alone for bulimia. The drug did cut binge and purge frequency in that trial. Bupropion was never approved or marketed for bulimia, so there was no indication to withdraw; what that seizure signal did instead was put both eating-disorder diagnoses into the contraindications, where they still sit today. If either diagnosis is anywhere in your history, say so at intake even if it was years ago and never formally recorded.

Read the letters after the name as dose ceilings and titration schedules rather than as different drugs. The sustained-release label sets 400 mg a day as the maximum, given as 200 mg twice daily, and only for those not responding to 300 mg. The extended-release label is stricter, and states it twice. Its dosage section gives 150 mg once daily as the starting dose and 300 mg once daily as the usual target dose, and its seizure warning opens with the risk of seizure is dose-related and the dose should not exceed 300 mg once daily. Same molecule, different ceilings, different spacing between doses.

A contradiction inside that same warning is worth naming, because a reader who finds it alone could take the wrong number from it. A few lines below the 300 mg instruction, the same section states that the risk of seizure can be reduced if the dose does not exceed 450 mg once daily and the titration rate is gradual. The label disagrees with itself. The 300 mg figure is the one carried in the Highlights section and in the dosage instructions for both indications, so 300 mg once daily is the extended-release ceiling to work from, and anything above it is something a prescriber has to justify against that warning rather than a routine step up.

The fourth ceiling belongs to smoking cessation. Bupropion sustained-release carries a separate label for quitting that starts at 150 mg a day for three days, then 300 mg a day as 150 mg twice daily at least eight hours apart, begun about a week before your quit date.

That label caps the dose at 300 mg a day explicitly to minimize seizure risk, which is 100 mg lower than the same formulation is allowed to reach when it is being prescribed for depression.

Liver function moves every one of those ceilings down. With moderate to severe hepatic impairment the extended-release label drops to 150 mg every other day and the sustained-release label to 100 mg daily or 150 mg every other day. Mild hepatic impairment and reduced kidney function both call for lower doses or wider spacing. This is one of the questions a remote prescriber has to ask you rather than infer.

The two figures every label carries are not a like-for-like formulation comparison, and it is worth being precise about that. The label reports about 0.1 percent, or one in a thousand, on sustained-release bupropion at up to 300 mg a day, and about 0.4 percent, thirteen in 3,200, on immediate-release bupropion in the 300 to 450 mg range. Those differ in release profile and in dose ceiling at once. The quantity the label consistently ties risk to is dose: estimated incidence rises almost tenfold between 450 and 600 mg a day.

A dedicated surveillance study puts a floor under the low end. Across 105 sites, roughly 3,100 adults with depression and no eating-disorder or seizure history took sustained-release bupropion up to 300 mg a day; two seizures occurred over eight weeks, about 0.06 percent, rising to three and roughly 0.10 percent with continuation treatment. Two further seizures followed intentional overdose and were excluded. Screening and a 300 mg ceiling do most of the work here.

The boxed warning is a separate matter, and its scope is narrower than reputation suggests. It is headed suicidal thoughts and behaviors, covering children, adolescents and young adults, and it records that the trials showed no increased risk in those aged 65 and older. Blood pressure deserves its own line: in the seasonal trials hypertension ran 2 percent against none on placebo, and treatment-emergent hypertension reached 6.1 percent when sustained-release bupropion was combined with a nicotine patch.

Almost nothing in the bupropion safety screen needs a physical exam, which is why remote prescribing suits it. What it does need is the questions being asked. Seizure history, any eating-disorder diagnosis past or present, current alcohol or sedative use and whether a taper is planned, MAOI exposure in the last fortnight, liver and kidney function, and your full medication list. An intake that collects a symptom score and a card number and nothing else has skipped the part that keeps the drug safe.

Blood pressure is the one measurement the label asks for by name: assess it before starting and monitor periodically during treatment. A service that never asks for a reading and offers no route to obtain one has left a labeled monitoring step unfilled. Worth knowing separately: bupropion can cause false-positive urine tests for amphetamines, which matters ahead of a workplace screen. Whether this drug suits you is a licensed clinician's decision, and none of this is medical advice.

When citalopram had already failed, 565 adults were randomized to add bupropion and 286 to add buspirone. Remission on the clinician-rated scale came out at 29.7 percent versus 30.1 percent, and on the self-rated scale 39.0 versus 32.9 percent, while dropout for intolerance ran 12.5 percent against 20.6 percent. A parallel arm switched drugs entirely: remission reached 21.3 percent on bupropion, 17.6 percent on sertraline and 24.8 percent on venlafaxine, with no significant difference between them.

A larger and more recent trial complicates the add-on story. Across 35 centers and 1,522 veterans, twelve-week remission ran 22.3 percent for switching to bupropion, 26.9 percent for adding it, and 28.9 percent for adding aripiprazole, with only the aripiprazole comparison against switching reaching significance. Anxiety was reported more often in both bupropion arms, at 24.3 and 22.5 percent against 16.6 percent. Neither strategy is obviously right, and the choice usually turns on which side effects you can live with.

The interaction to raise with a prescriber is CYP2D6. Bupropion and its metabolites inhibit that enzyme and can raise concentrations of venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline, haloperidol, risperidone, metoprolol, propafenone and flecainide. In a pharmacokinetic study, 150 mg twice daily followed by a single 50 mg dose of desipramine raised its peak level about twofold and its total exposure about fivefold, with the effect still measurable at least seven days after the last bupropion dose.

Bupropion is generic in every strength that matters, and the acquisition numbers are small enough to be worth stating plainly. In the federal National Average Drug Acquisition Cost file published on 2 September 2026, extended-release 300 mg sat at $0.10137 a tablet and 150 mg at $0.07872, with immediate-release 100 mg at $0.11511. Sustained-release 150 mg is listed twice, at $0.08238 across twenty-two national drug codes and $0.25144 across four. Every one of those rows is flagged generic.

One row breaks the pattern and it is instructive: the 450 mg extended-release tablet carried an acquisition cost of $8.02325 in the same file, on a single national drug code. That strength sits above the 300 mg once-daily ceiling the extended-release label sets, and it costs roughly eighty times what a generic 300 mg extended-release tablet does. Treat all of these as what a pharmacy pays. Retail markup, dispensing fees, telehealth consultation charges and shipping all sit on top, and they vary far more than the drug itself does.

You can judge a remote service on its intake before you pay anything. Does it ask about seizures, about eating disorders in any form, about alcohol and sedative use and any planned taper, about MAOIs in the last two weeks, about liver and kidney function? Does it collect every other medication you take and say who reviews it? Does it want a blood pressure reading? Those questions come straight off the label, and a service that skips them is not saving you time so much as moving risk onto you. Suitability, dose and formulation are a clinician's decision made with your history in front of them, and this page is information rather than a recommendation or medical advice.

Two further signals are worth weighting. First, whether a named licensed clinician in your state actually reviews the intake and is reachable afterward with a side-effect question, rather than a form triggering an automatic fill. Second, whether the plan states a target dose and a titration schedule up front instead of defaulting to the maximum.